JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul   Bogenberger James M   Geyer Holly L   Mesa Ruben A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

New JAK2 inhibitors for myeloproliferative neoplasms

By Quintáás-Cardama Alfonso   Verstovsek Srdan  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 961-972

Informa Healthcare

Access to resources Recommend Favorite

PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

By Hoeller Sylvia   Walz Christoph   Reiter Andreas   Dirnhofer Stephan   Tzankov Alexandar  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 53-62

Informa Healthcare

Access to resources Recommend Favorite

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

By  

Current Medicinal Chemistry, Vol. 19, Iss. 26, 2012-09 ,pp. : 4399-4413

Bentham Science Publishers

Access to resources Recommend Favorite

Immunotherapy for Myeloproliferative Neoplasms (MPN)

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 72-84

Bentham Science Publishers

Access to resources Recommend Favorite